Tempus AI 以 15 億美元收購 Personalis
Tempus AI buys Personalis for $1.5 billion
Updated at: July 21, 2026 at 02:00 AM
2026年7月20日，總部位於芝加哥的醫療保健科技領導者Tempus AI宣布了一項重大收購案，將收購知名的癌症檢測公司Personalis, Inc.。
On July 20, 2026, the Chicago-based healthcare technology leader Tempus AI announced a significant move to acquire Personalis, Inc., a prominent cancer-testing company.
這項策略性收購估值為15億美元，旨在鞏固Tempus AI在精準腫瘤學市場的地位。
Valued at $1.5 billion, this strategic acquisition aims to strengthen Tempus AI’s position in the precision oncology market.
該協議延續了雙方自2023年建立的成功合作關係，重點聚焦於高成長的微小殘留病灶（MRD）檢測領域。
The deal, which follows a successful partnership established in 2023, focuses on the high-growth area of minimal residual disease (MRD) testing.
透過整合Personalis的NeXT Personal MRD技術，Tempus計劃利用其龐大的商業版圖——覆蓋超過50%的美國腫瘤科醫師——來改善對癌症復發的檢測與治療監控。
By integrating Personalis’s NeXT Personal MRD technology, Tempus plans to leverage its vast commercial reach—covering over 50% of U.S. oncologists—to improve the detection and treatment monitoring of cancer recurrence.
儘管這筆交易代表了在創新領域的巨額投資，但市場起初反應謹慎，兩家公司的股價在消息公布後均出現下跌。
While the deal represents a substantial investment in innovation, the market reaction was initially cautious, with shares of both companies seeing a decline following the announcement.
投資人正密切關注整合過程及監管障礙，預計該收購將於2026年底至2027年初完成。
Investors are closely watching the integration process and regulatory hurdles, as the acquisition is expected to finalize between late 2026 and early 2027.
這次合併標誌著在利用人工智慧與基因檢測，為全國癌症患者提供更個人化且有效的護理方面邁出了重要的一步。
This merger marks a major step forward in using artificial intelligence and genetic testing to provide more personalized and effective care for cancer patients across the country.
